Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting

1 week ago 1

Channel Therapeutics (NYSE:CHRO) will implement a 10-for-1 reverse stock split, effective before market open on July 1, 2025.
The reverse split is aimed at meeting NYSE American listing requirements in anticipation of a planned merger and $50M capital raise.
Post-split, the company will change its name to Pelthos Therapeutics and begin trading under the new name on July 2, 2025.
The reverse split will reduce outstanding shares from ~6.49M to ~648,500.
Source: Press release

Recommended For You